Skip to main content
. Author manuscript; available in PMC: 2019 Jun 12.
Published in final edited form as: Nature. 2018 Dec 12;564(7735):273–277. doi: 10.1038/s41586-018-0774-y

Extended Data Fig. 10 |. MTR and ANP prevent cytokine release in syngeneic Eμ-ALL model without compromising anti-tumour efficacy.

Extended Data Fig. 10 |

a, b, Circulating catecholamines (left to right, n = 3, 4, 3, 4, 4, 4, 3, 4, 3, 4, 4, 4 per column/graph) (a) and murine cytokines IL-6 (n = 3 per column), KC (n = 3, 3, 3, 4, 3, 3, 4, 4, 3 per column), IL-1α (n = 3, 3, 3, 4, 3, 3, 4, 3, 3 per column) and G-CSF (n = 3, 3, 3, 4, 4, 3, 4, 3, 3 per column) (b), assessed at 24 and 72 h after mCART19 injection. Data are presented as means ± s.d. with individual data points shown, analysed by two-tailed t-test. c, BLI was performed before and 10 days after mCART19 cell injection, with or without ANP and MTR pre-treatment (n = 5 animals per group). BLI radiance was used to quantify the tumour burden during the treatment course (right). d, Percentage survival of Eμ-ALL-mice after mCART19 cell transfer (n = 8 mice per group). Survival differences were analysed by two-sided log-rank test.